Acute And Subacute Skin Manifestations Of Systemic Lupus Erythematosus Are Associated With An Earlier Response To Belimumab Than The Chronic Phenotype: Preliminary Data From The New Nation-Wide Cohort Of Belimumab In Real Life Setting Study—New Joint And Skin (BERLISS-NEJS)

June 2024

Luca Iaccarino, Marco Bracalenti, Margherita Zen … Andrea Doria

belimumab systemic lupus erythematosus SLE acute skin manifestations subacute skin manifestations chronic skin phenotypes CLASI-A index joint manifestations skin manifestations Benlysta lupus

Studysummary In this multicenter study, belimumab effectively reduced disease activity in systemic lupus erythematosus patients with joint and skin manifestations, showing significant improvement in acute and subacute skin types earlier than in chronic types, while no significant benefit was observed for nonspecific skin manifestations.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

Read the full study on doi.org →